Immunostimulatory monoclonal antibodies for cancer therapy
By I. Melero, Sandra Hervás-Stubbs, M. Glennie, D. Pardoll, Lieping Chen. Nature Reviews. Cancer, 2007
628 citations recorded by the source corpus.
Subfields: Immunology, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/8b05656b4ca0e495ba7812c7653f6d1706490dc3
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Immunology
- R. Flavell
- Shomyseh Sanjabi
- I. Melero
- C. Robert
- K. Margolin
- Shizuo Akira
- Alexander Y. Rudensky
- R. Medzhitov
Citations in the corpus
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. (2015, background): “The other approved agent was ipilimumab, a fully human immunoglobulin G1 monoclonal antibody that was designed to block cytotoxic T-lymphocyte antigen-4 to augment antitumor T-cell immunity.(4,5) Ipilimumab, either alone at 3 mg/kg in previously treated patients or at 10 mg/kg in combination with da”
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. (2013, background): “These strategies pioneered the field of immunostimulatory monoclonal antibodies for the therapy of cancer and are being followed by a panoply of targets on immune cells, which are under clinical development [17].”
- The polarization of immune cells in the tumour environment by TGFβ (2010, background): “This could be particularly problematic if TGFβ blockade is used in combination with other immune-activating agents, such as cytotoxic T lymphocyte antigen 4 (CTLA-4)- or programmed cell death 1 (PD1)-specific antibodies (which are also being evaluated as single agents in clinical trials and have sho”
- Cold Tumors: A Therapeutic Challenge for Immunotherapy (2019, background): “Lirilumab is a fully human antibody directed against KIR2DL-1,-2,-3 inhibitory receptors expressed predominantly on NK cells and is being tested in combination with ipilimumab or nivolumab for the treatment of patients bearing advanced solid malignancies (59).”